Syneos Health

Q: What industry does Syneos Health belong to?

Syneos Health is in the industry of: Healthcare Software , Software Development & Design , Software

Q: What is Syneos Health competition?

Syneos Health top competitors include: IQVIA Inc , PRA Health Sciences , Parexel International Corp , PPD Inc

Healthcare Software · North Carolina, United States · 28,000 Employees

Founded in 1998, Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a global Clinical Research Organization with a global Contract Commercial Organization. This helps their customers improve performance, reduce risk and speed much-needed therapies to patients worldwide. Syneos Health is headquartered in Morrisville, North Carolina.Read More

Contact

Who is Syneos Health

Headquarters

1030 Sync St, Morrisville, North Carolina, 27560, United States

Phone Number

(919) 876-9300

Website

www.syneoshealth.com

Revenue

$5.2B

Stock Symbol

SYNH

Industry

Healthcare Software

Software Development & Design

Software

Is this data correct?

View contact profiles from Syneos Health

Top Competitors of Syneos Health

IQVIA Inc
82,000
$8.6B
1
PRA Health Sciences
13,001
$5.5B
2
Parexel International Corp
17,500
$3.8B
3
PPD Inc
21,690
$5.9B
4
Covance Inc
15,004
$3.4B
5
Catalent Inc
19,000
$4.7B
6

Syneos Health Org Chart

Michelle Keefe

President, Medical Affairs &...

Phone

Jon Olefson

General Counsel, Corporate S...

Phone

Adam Tuckman

Chief Financial Officer, Com...

Phone

Syneos Health Email Formats

Syneos Health uses at least 5 email formats with first.last (ex. John.Smith@syneoshealth.com) being used 69.5% of the time

Syneos Health Email Formats		Percentage
first.last	John.Smith@syneoshealth.com	69.5%
first.last	John.Smith@inventivhealth.com	12.6%
first.last	John.Smith@incresearch.com	5.4%
first initials + last	JSmith@incresearch.com	1.1%
first + last	JohnSmith@syneoshealth.com	0%

Get Verified Emails

View Email Formats for Syneos Health

Syneos Health Company Metrics

Company Insights

Employee Growth Rate

Funding

Funding DateNov 07, 2022

RoundDebt

Amount$2.4B

InvestorsJPMorgan Chase

$2.4B

Total Funding Amount

$2.4B

Most Recent Funding Amount

Number of Funding Rounds

Acquisitions & Subsidiaries

Jul 18, 2022

AVOS Life Sciences

Jul 18, 2022

Cu-Tech

Jul 18, 2022

Synteract

Jul 15, 2021

Biosector 2

Jun 30, 2018

Avosconsulting.com

Aug 13, 2017

Campbell Alliance

See More Acquisitions & Subsidiaries

Syneos Health News & Media

Syneos Health Launches Medical Affairs Digital Amplifier
Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical ConferencesMORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific exchange. This integrated program seeks to ensure customers, and the clinicians they serve, have access to the
Mar 27, 2023
finance.yahoo.com
Thinking Differently About Indication Prioritization: Considerations for Making Better Strategic Decisions, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about current best practices for indication prioritization and common pitfalls. Attendees will gain insights into new clinical evaluation dimensions to improve assessments of clinical feasibility. The featured speaker will define ways of working across Commercial, R&D and RWE stakeholders to ensure appropriate assumptions relating to clinical strategies and plans are developed. (PRWeb March 22, 2023) Read the full story at https://www.prweb.com/releases/thinking_diffe
Mar 22, 2023
www.prweb.com
Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial Continuum
Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance
Mar 20, 2023
www.globenewswire.com
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has engaged Syneos Health (NASDAQ: SYNH) as the contract research organization (CRO) for its upcoming Phase 1/2 randomized, controlled clinical trial for the treatment of Type 1 Diabetes using the C
Mar 7, 2023
www.businesswire.com
StudyKIK Awarded SCOPE Participant Engagement Award for Oncology Study...
StudyKIK, a leading provider of clinical trial technologies, was twice awarded for products making a positive impact in the clinical research industry at the 2023 Summit for Clinical Ops Executives... (PRWeb February 28, 2023) Read the full story at https://www.prweb.com/releases/2023/2/prweb19191761.htm
Feb 28, 2023
www.prweb.com